Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Michael Rosenblatt joins Merck & Co

This article was originally published in Scrip

Executive Summary

Dr Michael Rosenblatt has been named executive vice-president and chief medical officer at Merck & Co. He will report directly to Merck's chairman, president and CEO, Richard Clark, will serve on the company’s executive committee and will oversee the company's global centre for scientific affairs. Dr Rosenblatt has served as dean of Tufts University School of Medicine since 2003. Before that, he was George R Minot Professor of Medicine at Harvard Medical School and chief of the division of bone and mineral metabolism research at Beth Israel Deaconess Medical Center.

You may also be interested in...



Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role

Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.

Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program

Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.

Lumicell’s Cancer Imaging Drug Faces Clinical Meaningfulness, Anaphylaxis Risk Questions At FDA Panel

US FDA advisory committee briefing documents say drug-device combo Lumisight (pegulicianine) is effective at picking up cancer but it is not clear whether that translates to patient benefit.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC006119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel